In GSE24080 set, the subgroups with EFS > 24 months and OS > 24 months showed lower expression of HNRNPA2B1compared to the subgroups with EFS ≤ 24 months and OS ≤ 24 months, (Fig. 6B and C, P = 0.0007, 0.0123, respectively), which was consistent with the results from GSE4204 and indicates that MM patients with higher HNRNPA2B1 expression had relatively decreased survival times. This evidence concerns the gene HNRNPA2B1 and Miyoshi myopathy.